Early Strides for Takeda’s Qdenga In Brazil, India Deal Adds New Dimension

Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s public vaccination program and outlines the contours, including pricing aspects, of the deal with Biological E for the dengue vaccine. The US IND application for the jab is still open.

Takeda's Qdenga rolls out in Brazil • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. appears to have made important early strides with Qdenga in Brazil, where the dengue tetravalent vaccine has been rolled out in a public program, even as the Japanese company sets out to bolster manufacturing capacity for the jab via a strategic alliance in India.

Dion Warren, head of multi-country organization, India and Southeast Asia, Takeda Pharmaceuticals, indicated that Brazil's Ministry of Health had in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip